Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Deferred Revenue (2020 - 2025)

Tango Therapeutics has reported Current Deferred Revenue over the past 6 years, most recently at $23.4 million for Q2 2025.

  • Quarterly results put Current Deferred Revenue at $23.4 million for Q2 2025, down 1.24% from a year ago — trailing twelve months through Jun 2025 was $23.4 million (down 1.24% YoY), and the annual figure for FY2024 was $17.6 million, down 31.37%.
  • Current Deferred Revenue for Q2 2025 was $23.4 million at Tango Therapeutics, up from $19.5 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for TNGX hit a ceiling of $34.0 million in Q1 2023 and a floor of $15.6 million in Q3 2024.
  • Median Current Deferred Revenue over the past 5 years was $25.8 million (2021), compared with a mean of $25.7 million.
  • Biggest five-year swings in Current Deferred Revenue: surged 35.91% in 2023 and later tumbled 42.37% in 2024.
  • Tango Therapeutics' Current Deferred Revenue stood at $26.0 million in 2021, then increased by 22.17% to $31.8 million in 2022, then fell by 19.26% to $25.7 million in 2023, then tumbled by 31.37% to $17.6 million in 2024, then surged by 32.67% to $23.4 million in 2025.
  • The last three reported values for Current Deferred Revenue were $23.4 million (Q2 2025), $19.5 million (Q1 2025), and $17.6 million (Q4 2024) per Business Quant data.